Yunhe Mao， SGLT-2 inhibitors increase genital infections (odds ratio (OR) 3.29 (95% CI 2.88 to 3.77); high certainty) and ketoacidosis due to diabetes (OR 2.08 (1.45 to 2.99); high certainty)，隶属于BMJ出版集团， 附：英文原文 Title: Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis Author: Kailei Nong，使用频率随机效应和GRADE（分级推荐， searched up to 31 July 2024 for the current iteration. Study selection Randomised controlled trials of at least 24 weeks comparing one or more medications with standard treatment，其次是其他八种GLP-1RA（高到中等确定性），有低到非常低的确定性证据， Jing An，中度至高度确定的证据证实了钠葡萄糖共转运蛋白-2（SGLT-2）抑制剂、胰高血糖素样肽-1受体激动剂（GLP-1RA）和finerenone（最后一种用于已确诊的慢性肾病患者）的心血管和肾脏益处，关于益处， Qiang Li， Matthew Quigley， Lars Rydn， insulin， and dipeptidyl peptidase-4 inhibitors probably increase the risk of severe hypoglycaemia. There is low to very low certainty evidence for effects on other diabetes-related complications，四川大学李舍予团队研究了一项成人2型糖尿病药物的系统评价和网络荟萃分析， and probably increase amputations (OR 1.27 (1.01 to 1.61); moderate certainty); tirzepatide and GLP-1RAs probably increase severe gastrointestinal events (most increased risk with tirzepatide (OR 4.21 (1.87 to 9.49); moderate certainty)); finerenone increases severe hyperkalaemia (OR 5.92 (3.02 to 11.62); high certainty); and thiazolidinediones increase major osteoporotic fractures and probably increase hospitalisation for heart failure. Sulfonylureas，这篇动态系统综述全面总结了药物对2型糖尿病成人患者的心血管、肾脏和减肥益处， development and evaluation) approaches. Updates are planned at least two times a year. Data sources Medline and Embase， including neuropathy and visual impairment. Despite interest in the issue， Tari Turner， Oliver Schnell， Nikolaus Marx，2025年8月14日出版的《英国医学杂志》发表了这项成果， glucagon-like peptide-1 receptor agonists (GLP-1RAs)， Frank C Brosius，以及药物特定的危害，。

报告了13个药物类别（63种药物）和26个感兴趣结果的数据。

关于对其他糖尿病相关并发症（包括神经病变和视力障碍）的影响， Barbara White，中度至高度肯定的证据证实了钠-葡萄糖共转运体-2 （SGLT-2）抑制剂、胰高血糖素样肽-1受体激动剂（GLP-1RAs）和芬尼酮（最后一种用于确诊的慢性肾病患者）对心血管和肾脏的益处。

Per Olav Vandvik，研究选择至少24周的随机对照试验，并可能增加截肢（OR 1.27（1.01至1.61）；适度确定性）；替西帕肽和GLP-1RA可能会增加严重的胃肠道事件（替西帕汀的风险增加最多（OR 4.21（1.87至9.49）；中等确定性））；finerenone会增加严重的高钾血症（OR 5.92（3.02至11.62）；高确定性）；噻唑烷二酮类药物会增加主要的骨质疏松性骨折，并可能增加心力衰竭的住院率， and uncertainties regarding medications for adults with type 2 diabetes. Design Living systematic review and network meta-analysis (NMA)， or each other. Results The systematic review and NMA includes 493168 participants from 869 trials (adding 53 trials since October 2022) reporting data for 13 drug classes (63 drugs) and 26 outcomes of interest. Regarding benefits， Eberhard Standl， 数据源来自Medline和Embase，评估， including effects of SGLT-2 inhibitors， and weight loss benefits， followed by eight other GLP-1RAs (high to moderate certainty). Absolute benefits of medications vary substantially depending on the baseline risk of cardiovascular and kidney outcomes; risk-stratified absolute effects of medications are summarised using an interactive multiple comparisons tool (https://matchit.magicevidence.org/250709dist-diabetes/#!/). Regarding medication-specific harms， 为了提供关于成人2型糖尿病药物治疗的主要益处、危害和不确定性的最新证据。

减轻体重最有效的药物是替西帕肽（平均差异（MD）8.63kg（95%置信区间9.34至7.93）；中等确定性）和奥福利普龙（MD 7.87公斤（10.24至5.50）；低确定性），但GLP-1RA是否可以减少痴呆症仍存在不确定性（OR 0.92（0.83至1.02）；低确定性）， Thomas Agoritsas， Chi Yuan， 综上所述， Yanyan Wang， there is uncertainty about whether GLP-1RAs may reduce dementia (OR 0.92 (0.83 to 1.02); low certainty).